Rate of development of mutation at codon 215 of HIV-1 reverse transcriptase and its predictive factors at the time of initiation of zidovudine therapy

European Journal of Clinical Investigation

Volumn 26, Issue 6, 1996, Pages 476-480

  Leal, M ^a   Rey, C ^a   Torres, Y ^a   Relimpio, F ^a   Pino, R ^b   Lissen, E ^a   Sanchez Quijano A ^a   Luque, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

HIV 1; Polymerse chain reaction; Resistance; Zidovudine

Indexed keywords

RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SPAIN;

EID: 0029886550     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.164315.x     Document Type: Article

References (36)

1. Fischl MA, Richman DD, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
2. Fischl MA, Richman DD, Hansen N et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990;112:727-37.
3. Volberding PA, Lagaskos SW, Koch MA et al. Idovudine in asymptomatic human immunodeficiency virus infection: a double-blind, placebo-controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl J Med 1990;322:941-9.
4. - counts greater than 400 per cubic millimeter. N Engl J Med 1993;329:297-303.
5. Tudor-Willians G, St Clair MH, McKinney RE et al. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992;339:15-9.
6. Montaner JSG, Singer J, Schlechter MT et al. Clinical correlates of in vitro resistance to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS 1993;7:189-96.
7. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4+ lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993;167:526-32.
8. D'Aquila RT, Johnson VA, Welles SL et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-9.
9. Calderón EJ, Torres Y, Medrano FJ et al. Emergence and clinical relevance of mutations associated with Zidovudine resistance in asymptomatic HIV-1 infected patients. Eur J Clin Microbiol Infect Dis 1995;14:512-9.
10. Boucher CAB, Tersmette M, Lange JMA et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk symptom-free individuals during therapy. Lancet 1990;336:585 90.
11. Rooke R, Tremblay M. Soudeyns H et al. Isolation of drug-resistant variants of HIV-1 from patients on long-term therapy. AIDS 1989;3:411-5.
12. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS 1990;3:743-6.
13. Land S, McGavin C, Lucas R, Birch C. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. J Infect Dis 1992;166:1139-42.
14. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance Case Definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-19.
15. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutation in DNA from HIV-infected lymphocytes. AIDS 1991;5:137-44.
16. Boucher CAB, Lange JMA, Miedema F et al. HIV-1 biolgical phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992;6:1259-64.
17. Koot M, Vos AH, Keet RP. De Goede RE et. al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992;6:49-54.
18. Benedetti J, Yuen K, Young L. 1L life tables survival functions. In: Dixon WJ. ed. BMDP Statistical Software Manual. Los Angeles: University of California Press, 1992,795-824.
19. Hopkin A. 2L survival analysis with covariates-Cox models. In: Dixon WJ. ed. BMDP Statistical Software Manual. Los Angeles: University of California Press, 1992,825-66.
20. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse trnascriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
21. Kellam P, Boucher CAB, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8.
22. Richamn DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras T. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J Infect Dis 1991;164:1075-81.
23. Boucher CAB, O'Sullivan E, Mulder JW et al. Ordered appearance of zidovudine resistance mutation during treatment of 19 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-10.
24. Luque H, Caruz A, Pineda JA, Torres Y, Larder B, Leal M. Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. J Infect Dis 1994;169:267-73.
25. Michael NL, Vahey M, Burke DS, Redfield RR. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infections in humans: evidence for viral replication in all stages of HIV disease. J Virol 1992;66:310-6.
26. Piatak M, Saag MS, Yang LC et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
27. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117 22
28. Ho DD, Neuman AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
29. + T cells from patients with human immunodeficiency virus (HIV) infection reflects rapid progression of immunosuppression and clinical disease. Ann Intern Med 1990;113:438-43.
30. + lymphocytes. Proc Natl Acad Sci USA 1994;91:1104-8.
31. Tindall B, Carr A, Cooper DA. Primary HIV infection: clinical, immunologic, and serologic aspects. In : Sande MA and Volberding PA, eds. The Medical Management of AIDS. Philadelphia: WB Saunders, 1994,105-29.
32. Pedersen C, Nielsen CM, Vestergaard BF, Gerstoft J, Krogs-gaard K, Nielsen JO. Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. Br Med J 1987;295:567-9.
33. Leal M, Pineda JA, Calderon ER, Rey C, Lissen E. Predictive value of the presence of p24 antigen in persons with antibodies to human immunodeficiency virus in Spain. Eur J Clin Microbiol Infect Dis 1989;8:244-7.
34. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
35. Tersmette M, De Goede RE, Al BMJ et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of synytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-32.
36. Torres Y, Program and abstract of the VIIème Conférence Internationale sur le SIDA en Afrique, Marrakesh, December 1993. Abstract N.OP. 221.